Immunome Inc. (IMNM) stock
IMNMNasdaqPharmaceutical PreparationsFiscal year ends December 31
$18.77+0.07 (+0.37%)
Close on Nov 13, 2026Market cap $2.13BP/E –Yield –
Immunome operating margin
Operating margin is operating income as a percentage of revenue.
Immunome's operating margin for the twelve months ending Mar 31, 2026 was -5947.9%. For fiscal 2025 it was -3228.8%, against -3382.4% the year before.
Annual operating margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -3228.8% | +153.5 |
| FY2024 | Dec 31, 2024 | -3382.4% | −2601.0 |
| FY2023 | Dec 31, 2023 | -781.4% | – |
Quarterly operating margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q2 FY2025 | Jun 30, 2025 | -1157.6% | +534.8 |
| Q1 FY2025 | Mar 31, 2025 | -1525.5% | +11331.6 |
| Q4 FY2024 | Dec 31, 2024 | -3030.3% | −556.4 |
| Q3 FY2024 | Sep 30, 2024 | -1736.2% | −1606.2 |
| Q2 FY2024 | Jun 30, 2024 | -1692.4% | −1557.0 |
| Q1 FY2024 | Mar 31, 2024 | -12857.0% | −12667.9 |
| Q4 FY2023 | Dec 31, 2023 | -2473.9% | – |
| Q3 FY2023 | Sep 30, 2023 | -130.0% | – |
| Q2 FY2023 | Jun 30, 2023 | -135.4% | – |
| Q1 FY2023 | Mar 31, 2023 | -189.1% | – |
See a number that looks wrong?